Media release –
Alcon flagship AcrySof® intraocular lens reaches 100 million implants and counting
- AcrySof® family of intraocular lenses (IOLs) continue legacy of being the most implanted cataract lens in the world
- New “100 Million Moments Made” campaign highlights how Alcon IOLs have created memories for tens of millions of patients
- Alcon continues commitment to expanding options for cataract patients worldwide
FORT WORTH, Texas, September 29, 2017 – Alcon, the global leader in eye care and a division of Novartis, announces that its innovative AcrySof® intraocular lens (IOL) platform for the treatment of cataracts reached a tremendous milestone – it has now been implanted more than 100 million times and counting. To mark this important accomplishment, Alcon is launching the “100 Million Moments Made” campaign which includes resources designed to showcase this accomplishment in markets around the globe.
“The 100 million implants milestone means that AcrySof® has improved the vision needs of more cataract patients than any other lens around the world, and, after two decades, remains the standard by which physicians measure all other IOLs,” said Max Wolf, Global Head, Intraocular Lenses, Alcon. “Reaching this milestone strengthens our commitment to continue pursuing new technologies, new tools and new techniques to help surgeons keep improving outcomes and address unmet patient needs.”
The first recorded implantation of an AcrySof® IOL was in the UK in 1990. Since its introduction, the platform has grown to include solutions for correcting astigmatism (AcrySof® IQ Toric) and presbyopia (AcrySof® IQ ReSTOR® and PanOptix®). The family of IOLs includes the following brands that are available in approximately 120 markets around the world: AcrySof® IQ, AcrySof® IQ Toric, AcrySof® IQ ReSTOR®, AcrySof® IQ ReSTOR® Toric, AcrySof® IQ PanOptix® and AcrySof® IQ PanOptix®Toric.
For more information on the AcrySof® platform of intraocular lenses, visit www.MyAlcon.com.
Important Information about IOLs and Cataract Surgery
As with any surgical procedure, there is risk involved. Potential complications accompanying cataract surgery include corneal endothelial damage, endophthalmitis, retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, and transient or persistent glaucoma. Surgeons should use careful preoperative evaluation and sound clinical judgement to decide the benefit/risk ratio before implanting a lens in a patient with one or more of the conditions identified in the product labeling, which can be found at www.Alcon.com.
Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our products touch the lives of more than 260 million people each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors, and there are millions more who are waiting for solutions to meet their eye care needs. Our purpose is reimagining eye care, and we do this through innovative products, partnerships with eye care professionals and programs that enhance access to quality eye care. Learn more at www.alcon.com.
Alcon is on Facebook. Like us at www.facebook.com/AlconEyeCare